会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • METHOD FOR THE ELECTROMAGENTIC INSULATION OF COMPONENTS OF AN ELECTRIC MOTOR
    • WO2023012662A1
    • 2023-02-09
    • PCT/IB2022/057162
    • 2022-08-02
    • UNIVERSITÀ DEGLI STUDI DI PADOVA
    • DONAZZON, RaffaeleBIANCHI, NicolaBERNARDO, Enrico
    • H01B3/00H01B3/46
    • The present disclosure relates to a method for the electromagnetic insulation of a first conductive element (1) and a second conductive element (2) of a stator and/or rotor of an electric motor. The method comprises the steps of: - coating the first conductive element (1) and the second conductive element (2) with at least on insulating compound (A, B) configured, during use, to insulate electromagnetically the first conductive element (1) and the second conductive element (2). The at least one insulating compound (A, B) comprises at least one preceramic polymer. - drying said first conductive element (1) and said second conductive element (2) coated with said at least one insulating compound (A, B). - coating said first conductive element (1) with a sealing compound (C) comprising a preceramic polymer and configured to favour adhesion of this second conductive element (2) to said first conductive element (1)' - assembling the first conductive element (1) and second conductive element (2) to form the stator of said electric motor; - heat treating the assembled first conductive element (1) and the said second conductive element (2). Said heat treatment comprises heating the first conductive element (1) and the second conductive element (2) up to a temperature of at least 350°C and subsequent cooling thereof. The present invention also relates to an electric motor comprising a first conductive element (1) and a second conductive element (2) electromagnetically insulated by means of the method described.
    • 5. 发明申请
    • RETROSPECTIVE RETROFITTING METHOD TO GENERATE A CONTINUOUS GLUCOSE CONCENTRATION PROFILE
    • 产生连续葡萄糖浓度分布的回归改造方法
    • WO2014128638A1
    • 2014-08-28
    • PCT/IB2014/059121
    • 2014-02-20
    • UNIVERSITÀ DEGLI STUDI DI PADOVA AREA TRASFERMIENTO DI TECNOLOGIA
    • Cobelli, ClaudioDel Favero, SimoneFacchinetti, AndreaSparacino, Giovanni
    • A61B5/145A61B5/1495A61B5/00
    • A61B5/7207A61B5/14532A61B5/1495A61B5/7275A61B5/7289G06F19/00
    • Continuous Glucose Monitoring (CGM) devices provide glucose concentration measurements in the subcutaneous tissue with limited accuracy and precision. Therefore, CGM readings cannot be incorporated in a straightforward manner in outcome metrics of clinical trials e.g. aimed to assess new glycaemic-regulation therapies. To define those outcome metrics, frequent Blood Glucose (BG) reference measurements are still needed, with consequent relevant difficulties in outpatient settings. Here we propose a "retrofitting" algorithm that produces a quasi continuous time BG profile by simultaneously exploiting the high accuracy of available BG references (possibly very sparsely collected) and the high temporal resolution of CGM data (usually noisy and affected by significant bias). The inputs of the algorithm are: a CGM time series; some reference BG measurements; a model of blood to interstitial glucose kinetics; and a model of the deterioration in time of sensor accuracy, together with (if available) a priori information (e.g. probabilistic distribution) on the parameters of the model. The algorithm first checks for the presence of possible artifacts or outliers on both CGM datastream and BG references, and then rescales the CGM time series by exploiting a retrospective calibration approach based on a regularized deconvolution method subject to the constraint of returning a profile laying within the confidence interval of the reference BG measurements. As output, the retrofitting algorithm produces an improved "retrofitted" quasi-continuous glucose concentration signal that is better (in terms of both accuracy and precision) than the CGM trace originally measured by the sensor. In clinical trials, the so-obtained retrofitted traces can be used to calculate solid outcome measures, avoiding the need of increasing the data collection burden at the patient level.
    • 连续葡萄糖监测(CGM)装置以有限的精度和精度提供皮下组织中的葡萄糖浓度测量。 因此,CGM读数不能以简单的方式纳入临床试验的结果指标。 旨在评估新的血糖调节疗法。 为了定义这些结果指标,仍然需要频繁的血糖(BG)参考测量,从而在门诊设置中相应的困难。 在这里,我们提出了一种“改造”算法,通过同时利用可用的BG参考(可能非常稀疏地收集)的高精度和CGM数据的高时间分辨率(通常是嘈杂的并且受到显着的偏差影响)来产生准连续时间BG分布。 算法的输入是:CGM时间序列; 一些参考BG测量; 血液间质葡萄糖动力学模型; 以及传感器精度的时间劣化的模型,以及(如果可用的话)对模型的参数的先验信息(例如概率分布)。 该算法首先检查在CGM数据流和BG引用上是否存在可能的伪像或异常值,然后通过利用基于正则化反卷积方法的回溯校准方法来调整CGM时间序列,该方法受到限制,返回在 参考BG测量的置信区间。 作为输出,改进算法产生改进的“改进的”准连续葡萄糖浓度信号,其比原始由传感器测量的CGM迹线更好(在精度和准确度方面)。 在临床试验中,如此获得的改进痕迹可用于计算固体结果测量,避免在患者水平上增加数据收集负担。
    • 8. 发明申请
    • USE OF AMIODARONE AND AMIODARONE ANALOGUES AS ANTIVIRAL AGENTS
    • 阿米达隆和阿米达龙类似物作为抗病毒药物的使用
    • WO2008044261A1
    • 2008-04-17
    • PCT/IT2007/000712
    • 2007-10-11
    • UNIVERSITÀ DEGLI STUDI DI PADOVABARITUSSIO, Aldo
    • BARITUSSIO, Aldo
    • A61P31/12A61K31/343
    • A61K31/343
    • The present invention regards the use of amiodarone, and structurally related compounds, as antivirals. Amiodarone, which is widely used to treat cardiac arrhythmias, inhibits the spreading in vitro of the coronavirus responsible of the Severe Acute Respiratory Syndrome (SARS) by acting after the delivery of the viral genome into the cytoplasm. The antiviral effect of amiodarone appears to be related to changes in the host cell, rather than to a direct effect on the SARS coronavirus and starts at concentrations close to those reached in patients treated for arrhythmias. Although the fine mechanism of the antiviral activity remains to be clarified, pharmaceutical preparations containing amiodarone or structurally related compounds could be used for the treatment or the prevention of infections by the SARS coronavirus or viruses having similar strategies of infection.
    • 本发明涉及胺碘酮和结构相关化合物作为抗病毒剂的用途。 广泛用于治疗心律失常的胺碘酮通过在病毒基因组递送到细胞质中后通过作用来抑制冠状病毒在严重急性呼吸综合征(SARS)中的扩散。 胺碘酮的抗病毒效果似乎与宿主细胞的变化有关,而不是对SARS冠状病毒的直接作用,并且以接近于治疗心律失常的患者达到的浓度开始。 虽然抗病毒活性的精细机制尚待澄清,但含有胺碘酮或结构相关化合物的药物制剂可用于治疗或预防SARS冠状病毒或具有相似感染策略的病毒的感染。
    • 9. 发明申请
    • SYNTHESIS OF SILICA PROTECTIVE FILMS BY TIN-CATALIZED SOL-GEL PROCESS
    • 通过催化溶胶凝胶工艺合成二氧化硅保护膜
    • WO2007122662A1
    • 2007-11-01
    • PCT/IT2007/000297
    • 2007-04-20
    • UNIVERSITÀ DEGLI STUDI DI PADOVABERTONCELLO, RenzoDAL BIANCO BarbaraVOLTOLINA, Stefano
    • BERTONCELLO, RenzoDAL BIANCO BarbaraVOLTOLINA, Stefano
    • C03C17/25C01B33/154C01B33/16C03C1/00C03B19/12
    • C03C1/008C03C17/02C03C17/25C03C2217/213C03C2218/113C23C26/00C23C30/00
    • The present invention is a method for the preparation of sol-gel precursors' solutions, using Lewis acids as catalysts. In particular this method is very efficient if Sn(IV) in aqueous solution is used as catalyst. The pH value of solutions can be varied between 4 and 7, according to the amount of catalyst. The composition of solutions can be planned in order to achieve the best results regarding gelation time and film morphology, according to the particular material that has to be coated and/or protected. All operative parameters, except pH and temperature, for formation and deposition of glass films are controlled according to what is reported in literature for the classical sol-gel method. The present invention produces a film constituted of glassy silica. Silica glass is the most durable glass and also the most resistant to chemical and physical attacks. It shows good features of homogeneity, purity, weathering resistance and transparency. The nature of its constituents (silicon and oxygen) makes it highly compatible with glass substrates. The present method involves: • The deposition of films in nearly neutral pH conditions, in order to avoid degradation of objects sensitive to acid environment; • The substitution of the heat treatment to increase the film density with a slow drying process carried out at ambient temperature, in order to avoid damaging of the substrate.
    • 本发明是使用路易斯酸作为催化剂制备溶胶 - 凝胶前体溶液的方法。 特别地,如果使用水溶液中的Sn(IV)作为催化剂,则该方法非常有效。 根据催化剂的数量,溶液的pH值可以在4和7之间变化。 根据必须涂覆和/或保护的具体材料,可以规划溶液的组成以便获得关于凝胶化时间和膜形态的最佳结果。 根据用于经典溶胶 - 凝胶法的文献报道的所有操作参数,除pH和温度外,用于形成和沉积玻璃膜。 本发明产生由玻璃状二氧化硅构成的膜。 硅玻璃是最耐用的玻璃,也是最耐化学和物理攻击的玻璃。 它具有均匀性,纯度,耐候性和透明度的良好特征。 其成分(硅和氧)的性质使其与玻璃基板高度兼容。 本方法涉及:将膜沉积在接近中性的pH条件下,以避免对酸性环境敏感的物质降解; 替代热处理以在环境温度下进行的缓慢干燥过程增加膜密度,以避免损坏基材。